治疗银屑病的IL-17 抑制剂报告研究包括如下几个方面:医院及诊所、药店、其他如您需要更详细的信息,建议查看QYResearch机构发布的完整版目录内容(目录+图表)或申请报告样本可点击链接:https://www.qyresearch.com.cn/reports/4378285/il-17-inhibitors-for-psoriasis 关于我们:QYResearch(北京恒州博智国际信息咨询有限...
Vigibase®Several gastrointestinal symptoms and chronic inflammatory bowel diseases (IBD) have been reported after therapy with IL inhibitors. To date, however, no study has shown a clear association between these drugs and IBD onset. We searched on Vigibase to investigate reporting prevalence, ...
Inflammopharmacology. 2022 Apr;30(2):435-451. Immune-related adverse events(irAEs)in ankylosing spondylitis(AS)patients treated with interleukin(IL)-17 inhibitors: a systematic review and meta-analysis https://pubmed.ncbi.nlm.nih.gov/35188599/...
参考资料: Inflammopharmacology. 2022 Apr;30(2):435-451. Immune-related adverse events(irAEs)in ankylosing spondylitis(AS)patients treated with interleukin(IL)-17 inhibitors: a systematic review and meta-analysis /35188599/©2022 Baidu |由 百度智能云 提供计算服务 | 使用百度前必读 | 文库协议 ...
原始出处: Yufeng Yin, et al., Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-ysis. Arthritis Res Ther. 2020 May 12;22(1):111. doi: 10.1186/s13075-020-02208-w.
独有典故: Yufeng Yin, et al., Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-ysis. Arthritis Res Ther. 2020 May 12;22(1):111. doi: 10.1186/s13075-020-02208-w.
Inflammopharmacology. 2022 Apr;30(2):435-451. Immune-related adverse events(irAEs)in ankylosing spondylitis(AS)patients treated with interleukin(IL)-17 inhibitors: a systematic review and meta-analysis https://pubmed.ncbi.nlm./35188599/
原始中有: Yufeng Yin, et al., Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-ysis. Arthritis Res Ther. 2020 May 12;22(1):111. doi: 10.1186/s13075-020-02208-w.
原始中有: Yufeng Yin, et al., Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-ysis. Arthritis Res Ther. 2020 May 12;22(1):111. doi: 10.1186/s13075-020-02208-w.
Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation Description : Recombinant Murine IL-17 produced in E.Coli is a homodimeric, non-glycosylated polypeptide chain containing a total of 266 amino acids and having a molecular mass of ...